Sirnaomics Ltd. · HKEX:2257
Sirnaomics — FY2021 Earnings Presentation
25 slides from Sirnaomics's earnings presentation, March 2022
Slide 1: FY2021 Annual Result Presentation
Sirnaomics Ltd. [2257.HK] (Incorporated in the Cayman Islands with limited liability) FY2021 Annual Result Presentation 0
Slide 2: Disclaimer
Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by
Slide 3: Presenters
Presenters Patrick Lu 陆阳, PhD Michael V. Molyneaux, MD, MBA PhD, Founder, Chairman of the Board, Executive Director, Executive Director, CMO President & CEO 28+ years of experience 20+ years of experience David Mark Evans, PhD Nigel Yip 叶永基 Executive Director, CSO China CFO 25+ years of experience 1
Slide 4: Agenda
Agenda 01 – Company Overview 02 - Pipeline Updates 03 - Future Milestones and Catalysts 04 - Financial Highlights 3
Slide 5: Company Overview
sirna@mics Advancing RNAi Therapeutics Company Overview
Slide 6: A RNA Therapeutic Innovator on a Global Stage
A RNA Therapeutic Innovator on a Global Stage Sirnaomics is the first clinical stage RNA therapeutic company to have a strong presence in both the U.S. and China, powered by advanced RNAi & mRNA technologies ◼ Polypeptide nanoparticle (PNP) Platform: – High delivery efficiency, validated safety, hig
Slide 7: Major Accomplishments
Major Accomplishments Well Capitalized Executing R&D strategy Organization Expansion ◼ Successful IPO in Dec 2021: ◼ Global R&D employees: 123 ◼ 175 employees ~ US$ 55m net proceeds ◼ STP705 - Initiated trials in the ◼ Talent development and raised (post shoes) U.S. for the treatment of acquisition
Slide 8: Pipeline Updates
sirna@mics Advancing RNAi Therapeutics Pipeline Updates
Slide 9: Delivery Technology Platforms and Therapeutic Areas
Delivery Technology Platforms and Therapeutic Areas PNP Platform: GalNAc Platform: (Clinical Stage) (Clinical Candidate) CPP GalAhead® siRNA PDoV-GalNAc HKP and HKP(+H) are well suited for siRNA Therapeutics or mRNA Therapeutics and Vaccine Deliveries mRNA Cancer Fibrosis Diseases Viral Infections L
Slide 10: Broad and Deep Product Pipeline
Broad and Deep Product Pipeline Delivery IND Candidate Gene Targets Indications Pre-clinical IND Phase I Phase II Phase III Rights Platform Enabling US isSCC Global China (MRCT)2 BCC US Global STP705* TGF-β1/COX-2 PNP-IT US Liver Cancer1 (Basket) ** Global China (MRCT)3 Liver Cancer, combo with anti
Slide 11: STP705 Provides Positive Clinical Readouts for isSCC
STP705 Provides Positive Clinical Readouts for isSCC Study Groups 10 ug Group 20 ug Group 30 ug Group 60 ug Group 120 ug Group (N=5) (N=5) (N=5) (N=5) (N=5) 3/5 3/5 4/5 5/5 4/51 Histological Clearance 60% 60% 80% 100% 80% Average Skin Response Scores Pre-treatment 3.6 3.2 3.6 4.2 2.8 Post-treatment
Slide 12: STP705 Phase IIb for the Treatment of isSCC
STP705 Phase IIb for the Treatment of isSCC ◼ Initiated Phase IIb clinical trial for the treatment of isSCC in May 2021 in the U.S. ◼ Filed our IND in China for a Phase IIb clinical trial for isSCC that would be part of a global multicenter clinical trials ◼ Our Phase IIb clinical trials for STP705
Slide 13: STP705 Initial Clinical Data for BCC
STP705 Initial Clinical Data for BCC Cohort A: 30 μg Cohort B: 60 μg Cohort C: 90 μg (N=5) (N=5) (N=5) 1/5 3/5 3/5 Histological Clearance 20% 60% 60% Average Skin Response Scores Pre-treatment 3.2 2.8 2.6 Post-treatment 2.4 2.6 2.6 ◼ Initiated Phase II clinical trial for the treatment of BCC in Janu
Slide 14: STP705 Phase I for the Treatment of Fat Sculpting
STP705 Phase I for the Treatment of Fat Sculpting Porcine model shows potential in fat sculpting Protocol, study design and endpoints ◼ We expect to initiate our Phase I study to evaluate the Control Group safety and tolerability of subcutaneous injection of STP705 in adult subjects undergoing abdom
Slide 15: STP707 – Updates on ongoing clinical trials
STP707 – Updates on ongoing clinical trials Oncology, Multiple Solid Tumors Anti-Fibrosis, PSC Protocol, study design and endpoints Protocol, study design and endpoints ◼ In February 2022, we announced the launch of a ◼ In November 2021, we filed an IND for PSC, a rare Phase I clinical trial for the
Slide 16: GalAhead-GalNAc-FXI: STP122G
GalAhead-GalNAc-FXI: STP122G Long-Lasting Target Knockdown Effect and Strong Therapeutic Benefit STP122G therapeutic effect at 33 weeks Strong Therapeutic Benefit Groups: Activated Partial Thromboplastin Time All groups 2x, 3x Group: 3x Prothrombin Time IND enabling, expect to file IND in 2H 2022 15
Slide 17: STP908: Anti-SARS-Cov2 Activity
STP908: Anti-SARS-Cov2 Activity Mouse Model with SA-WA (2020) Strain, IV x 4, N = 10 ◼ STP908 targets two highly conserved viral sequences from most Coronaviruses, including SARS (2003) and many SARS- A B CoV2 Variants – including SARS Cov2 Omicron and Delta A B Morbidity data Morbidity data Mortali
Slide 18: RIM730: A mRNA Vaccine against SARS-CoV2 Infection
RIM730: A mRNA Vaccine against SARS-CoV2 Infection RIM730-induced mouse serum activity RIM730 challenged mouse serum neutralized RIM730-induced antibodies viral proteins from SARS Covid2 viruses block viral infection and provide protection Day 14 Day 14 S1 Protein RBD Protein Day 35 Day 35 S1 Protei
Slide 19: Guangzhou Fill & Finish Plant with GMP Compliance
Guangzhou Fill & Finish Plant with GMP Compliance ◼ The siRNA PNP preparation production facility has been built in 2021 ◼ An anticipated annual capacity of producing around 50,000 vials of lyophilized human injectables ◼ Preparation, production and freeze-drying of nano preparations ◼ Successfully
Slide 20: Future Milestones and Catalysts
Part 3 Future Milestones and Catalysts 19
Slide 21: Pipeline Future Milestones
Pipeline Future Milestones Candidates 2021 2022 2023 isSCC Initiated Phase IIb trial Interim data readout Potential roll-out of trials globally Interim data BCC 1st Patient dosed Final data readout readout Liver Cancer (Basket) Initiated Phase I trial Interim data readout STP705 Keloid scarless heal
Slide 22: Financial Overview
sirna@mics Advancing RNAi Therapeutics Financial Overview
Slide 23: Profit and Loss
Profit and Loss 2021 2020 Ref US$ (m) US$ (m) 1. Changes in fair value of financial liabilities at Revenue nil nil FVTPL: Increase in fair value loss (non-cash) on Other income, other gains and preferred shares and other financial liabilities due to 0.1 1.0 losses increase in valuation of the Compan
Slide 24: Cash flow
Cash flow Ref 2021 cash flow US$ (m) 1. Net cash used in operating activities: Cash and cash equivalents at Contributed by our continual business expansion 103.1 January 1 including both R&D and G&A. Cash spending in operating activities have increased from US$19m Net cash used in operating 1 (57.0)
Slide 25: Q&A
SITna@mics icing RNAi Therapeutic: Q&A